132 related articles for article (PubMed ID: 34787019)
1. Expressing
Huang Y; Feng L; Bao Y; Zhang Y; Liang J; Mao Q; Li J; Jiang C
Exp Biol Med (Maywood); 2022 Mar; 247(5):426-432. PubMed ID: 34787019
[TBL] [Abstract][Full Text] [Related]
2. Differential cellular responses to prolonged LDR-IR in MLH1-proficient and MLH1-deficient colorectal cancer HCT116 cells.
Yan T; Seo Y; Kinsella TJ
Clin Cancer Res; 2009 Nov; 15(22):6912-20. PubMed ID: 19861440
[TBL] [Abstract][Full Text] [Related]
3. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation.
Davis TW; Wilson-Van Patten C; Meyers M; Kunugi KA; Cuthill S; Reznikoff C; Garces C; Boland CR; Kinsella TJ; Fishel R; Boothman DA
Cancer Res; 1998 Feb; 58(4):767-78. PubMed ID: 9485033
[TBL] [Abstract][Full Text] [Related]
4. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Park JM; Huang S; Tougeron D; Sinicrope FA
PLoS One; 2013; 8(5):e65369. PubMed ID: 23724141
[TBL] [Abstract][Full Text] [Related]
5. MLH1 deficiency enhances radiosensitization with 5-fluorodeoxyuridine by increasing DNA mismatches.
Flanagan SA; Krokosky CM; Mannava S; Nikiforov MA; Shewach DS
Mol Pharmacol; 2008 Sep; 74(3):863-71. PubMed ID: 18535288
[TBL] [Abstract][Full Text] [Related]
6. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
7. MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal.
Fedier A; Poyet C; Perucchini D; Boulikas T; Fink D
Anticancer Drugs; 2006 Mar; 17(3):315-23. PubMed ID: 16520660
[TBL] [Abstract][Full Text] [Related]
8. Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.
Yan T; Schupp JE; Hwang HS; Wagner MW; Berry SE; Strickfaden S; Veigl ML; Sedwick WD; Boothman DA; Kinsella TJ
Cancer Res; 2001 Nov; 61(22):8290-7. PubMed ID: 11719462
[TBL] [Abstract][Full Text] [Related]
9. MLH1 mediates cytoprotective nucleophagy to resist 5-Fluorouracil-induced cell death in colorectal carcinoma.
Manzoor S; Saber-Ayad M; Maghazachi AA; Hamid Q; Muhammad JS
Neoplasia; 2022 Feb; 24(2):76-85. PubMed ID: 34952246
[TBL] [Abstract][Full Text] [Related]
10. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
[TBL] [Abstract][Full Text] [Related]
11. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
[TBL] [Abstract][Full Text] [Related]
12. Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Tentori L; Leonetti C; Muzi A; Dorio AS; Porru M; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Int J Oncol; 2013 Jul; 43(1):210-8. PubMed ID: 23653048
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity.
Kuo ML; Hwang HS; Sosnay PR; Kunugi KA; Kinsella TJ
Cancer J; 2003; 9(4):277-85. PubMed ID: 12967138
[TBL] [Abstract][Full Text] [Related]
14. Targeting mitochondrial DNA polymerase gamma for selective inhibition of MLH1 deficient colon cancer growth.
Somuncu B; Ekmekcioglu A; Antmen FM; Ertuzun T; Deniz E; Keskin N; Park J; Yazici IE; Simsek B; Erman B; Yin W; Erman B; Muftuoglu M
PLoS One; 2022; 17(6):e0268391. PubMed ID: 35657956
[TBL] [Abstract][Full Text] [Related]
15. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
[TBL] [Abstract][Full Text] [Related]
16. Presence of MLH1 protein aggravates the potential of the HSP90 inhibitor radicicol to sensitize tumor cells to cisplatin.
Fedier A; Stuedli A; Fink D
Int J Oncol; 2005 Dec; 27(6):1697-705. PubMed ID: 16273226
[TBL] [Abstract][Full Text] [Related]
17. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells.
Berry SE; Garces C; Hwang HS; Kunugi K; Meyers M; Davis TW; Boothman DA; Kinsella TJ
Cancer Res; 1999 Apr; 59(8):1840-5. PubMed ID: 10213489
[TBL] [Abstract][Full Text] [Related]
18. Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner.
Fedier A; Erdmann R; Boulikas T; Fink D
Int J Oncol; 2006 Nov; 29(5):1303-10. PubMed ID: 17016665
[TBL] [Abstract][Full Text] [Related]
19. Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1.
Hinrichsen I; Ernst BP; Nuber F; Passmann S; Schäfer D; Steinke V; Friedrichs N; Plotz G; Zeuzem S; Brieger A
Mol Cancer; 2014 Jan; 13():11. PubMed ID: 24456667
[TBL] [Abstract][Full Text] [Related]
20. MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.
Li Y; Zhang S; Wang Y; Peng J; Fang F; Yang X
BMC Cancer; 2018 Dec; 18(1):1294. PubMed ID: 30594176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
